Cargando…
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
BACKGROUND: The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility in personalising breast cancer treatment in a clinical practice setting, throu...
Autores principales: | Barton, S, Zabaglo, L, A'Hern, R, Turner, N, Ferguson, T, O'Neill, S, Hills, M, Smith, I, Dowsett, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364112/ https://www.ncbi.nlm.nih.gov/pubmed/22531639 http://dx.doi.org/10.1038/bjc.2012.166 |
Ejemplares similares
-
Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study
por: Yeo, B, et al.
Publicado: (2015) -
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
por: Sheri, A., et al.
Publicado: (2017) -
Who would have thought a single Ki67 measurement would predict long-term outcome?
por: Dowsett, Mitch, et al.
Publicado: (2009) -
Short-term presurgical treatment for all?
por: Dowsett, Mitch, et al.
Publicado: (2007) -
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study
por: Lopez-Knowles, Elena, et al.
Publicado: (2022)